Longboard Pharmaceuticals (LBPH) S-3MEF Registration of additional securities for an S-3

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated March 2, 2023, with respect to the financial statements of Longboard Pharmaceuticals, Inc., incorporated herein by reference, and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

San Diego, California

January 3, 2024